- Telehealth Visits
- Insurance plan information
Luke M. Judge, MD, PhD
Neonatology- Telehealth Visits
- Insurance plan information
Luke M. Judge, MD, PhD
Neonatology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Luke Judge is a pediatrician who specializes in caring for infants in the intensive care nursery. He also resuscitates newborns when needed during high-risk deliveries. At the Fetal Treatment Center, he provides prenatal counseling to women with complicated pregnancies.
Judge's research focuses on genetic diseases of the heart and skeletal muscle. He employs an approach called ""disease modeling in a dish,"" which involves growing human cell types and tissues in the laboratory.
Judge earned his undergraduate degree from Pomona College. He earned his doctoral and medical degrees from the University of Washington. He completed a residency in pediatrics and a fellowship in neonatal-perinatal medicine at UCSF.
Judge is a member of the American Academy of Pediatrics and International Society for Stem Cell Research.
Education & training
Board certification
- Neonatal-Perinatal Medicine, American Board of Pediatrics
- Pediatrics, American Board of Pediatrics
Fellowship
- Neonatology, UCSF Graduate Medical Education
Residency
- Pediatrics, UCSF Graduate Medical Education
Degree
- MD, University of Washington School of Medicine
My expertise
Specialties
- Neonatology
Conditions
- Adult Congenital Heart Disease
Clinical Trials query: q=health_gateway_id_ss%3A%28%221476%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%221476%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.